2024
Shifting the paradigm of type 1 diabetes: a narrative review of disease-modifying therapies
O’Donovan A, Gorelik S, Nally L. Shifting the paradigm of type 1 diabetes: a narrative review of disease-modifying therapies. Frontiers In Endocrinology 2024, 15: 1477101. PMID: 39568817, PMCID: PMC11576206, DOI: 10.3389/fendo.2024.1477101.Peer-Reviewed Original ResearchDisease modifying therapiesStages of T1DFood and Drug AdministrationType 1 diabetesLong-term insulin dependenceDestruction of pancreatic beta cellsModifying therapiesDiagnosis of type 1 diabetesClinical diagnosis of T1DClinical diseasePathogenesis of T1DDetection of autoantibodiesDiagnosis of T1DNarrative reviewSymptoms of hyperglycemiaPancreatic beta cellsMechanism of actionAutoimmune conditionsInsulin-DependentPublished trialsGlycemic changesDrug AdministrationInsulin deficiencyTherapyClinical diagnosisThe immunology of type 1 diabetes
Herold K, Delong T, Perdigoto A, Biru N, Brusko T, Walker L. The immunology of type 1 diabetes. Nature Reviews Immunology 2024, 24: 435-451. PMID: 38308004, PMCID: PMC7616056, DOI: 10.1038/s41577-023-00985-4.Peer-Reviewed Original ResearchType 1 diabetesT cellsDestruction of pancreatic B-cellsImmune-targeted interventionsTarget T cellsPathogenesis of T1DB-cell massPancreatic B-cellsAutoimmune destructionB cellsGlucose dysregulationImmune mechanismsImmune systemNatural historyDisease pathogenesisT1DRegulatory approvalTreatment of individualsDiscovery of insulinPathogenesisDiseaseSeminal discoveriesImmunotherapy
2022
Gene Expression Signatures Reveal Common Virus Infection Pathways in Target Tissues of Type 1 Diabetes, Hashimoto’s Thyroiditis, and Celiac Disease
Yin M, Zhang Y, Liu S, Huang J, Li X. Gene Expression Signatures Reveal Common Virus Infection Pathways in Target Tissues of Type 1 Diabetes, Hashimoto’s Thyroiditis, and Celiac Disease. Frontiers In Immunology 2022, 13: 891698. PMID: 35795668, PMCID: PMC9251511, DOI: 10.3389/fimmu.2022.891698.Peer-Reviewed Original ResearchConceptsHashimoto's thyroiditisCeliac diseaseAutoimmune diseasesTarget tissuesAutoimmune disordersHuman T-lymphotropic virus type 1Type 1 diabetes patientsMore autoimmune disordersPathogenesis of T1DType 1 diabetesCommon gene expression changesVirus type 1Gene expression signaturesSimplex infectionVirus infection pathwaysDiabetes patientsInfluenza APositive individualsVirus infectionT1DThyroiditisImmune systemType 1Gene signatureSimilar molecular signatures
2013
Identification of posttranslational modified autoantigens in Type 1 diabetes. (P4152)
Yang M, Connolly S, Wen L, Herold K, Mamula M. Identification of posttranslational modified autoantigens in Type 1 diabetes. (P4152). The Journal Of Immunology 2013, 190: 172.3-172.3. DOI: 10.4049/jimmunol.190.supp.172.3.Peer-Reviewed Original ResearchNOD miceType 1 diabetesDiabetes-prone NOD miceEarly-onset diabetic patientsPre-diabetic NOD miceDiabetic NOD miceT cell autoimmunityPathogenesis of T1DPancreatic islet proteinsCell autoimmunityDiabetic patientsImmune toleranceRheumatoid arthritisMultiple sclerosisAutoimmune diseasesMurine modelTarget organsTherapeutic targetSelf proteinsPancreatic isletsIslet proteinsMiceOxidative stressPeripheral erythrocytesDiabetes
2012
Type 1 diabetes therapy beyond T cell targeting: monocytes, B cells, and innate lymphocytes.
Wong F, Wen L. Type 1 diabetes therapy beyond T cell targeting: monocytes, B cells, and innate lymphocytes. The Review Of Diabetic Studies 2012, 9: 289-304. PMID: 23804267, PMCID: PMC3740697, DOI: 10.1900/rds.2012.9.289.Peer-Reviewed Original ResearchConceptsInnate lymphocytesB cellsT cell targetingNatural killer cellsRecent clinical trialsPathogenesis of T1DType 1 diabetesType 1 diabetes therapyKiller cellsSpecific therapyClinical trialsT cellsDisease processDiabetes therapyMultifactorial diseaseCell pathwaysMultiple cell typesDiabetesT1DLymphocytesTherapyMonocytesDiseaseSuitable targetCell types
2007
Anti-CD20 Therapy in NOD Model of Type 1 Diabetes (131.26)
Hu C, Rodriguez D, Du W, Ahuja A, Wong F, Shlomchik M, Wen L. Anti-CD20 Therapy in NOD Model of Type 1 Diabetes (131.26). The Journal Of Immunology 2007, 178: s242-s242. DOI: 10.4049/jimmunol.178.supp.131.26.Peer-Reviewed Original ResearchTransgenic NOD miceB cellsNOD miceT cellsHuman CD20Pre-diabetic stageB-cell depletionRegulatory T cellsOnset of diabetesPathogenesis of T1DTGF-β productionType 1 diabetesAbstract B cellsCD20 therapyImportant APCsDiabetes onsetT1D patientsNOD modelAutoimmune diseasesCell depletionClinical trialsPreclinical studiesParticular therapyHuman studiesCD20Distinct local immunogenic stimuli dictate differential requirements for CD4+ and CD8+ T cell subsets in the pathogenesis of spontaneous autoimmune diabetes
Rajagopalan G, Mangalam A, Sen M, Kudva Y, David C. Distinct local immunogenic stimuli dictate differential requirements for CD4+ and CD8+ T cell subsets in the pathogenesis of spontaneous autoimmune diabetes. Autoimmunity 2007, 40: 489-496. PMID: 17966038, DOI: 10.1080/08916930701649836.Peer-Reviewed Original ResearchConceptsIncidence of diabetesPathogenesis of T1DRat insulin promoterTransgenic mouse modelMouse modelHLA-DQ8 transgenic miceMurine type 1 diabetesDouble transgenic mouse modelMHC class II associationsLocal inflammatory stimuliSpontaneous autoimmune diabetesT cell subsetsClass II associationsType 1 diabetesAutoimmune diabetesImmunogenic stimulusProinflammatory cytokinesCell subsetsCostimulatory moleculesTNF-alphaT cellsInflammatory stimuliDiabetesTransgenic miceCD4
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply